We’re pleased to announce our latest partnership with Willis Knighton Cancer Center. They’ve integrated MyoStrain into their radiotherapy program to enhance early detection of cardiotoxicity in cancer patients. With our rapid, 10-minute MRI-based cardiac assessment—requiring no contrast—clinicians can monitor subtle changes in heart function to tailor patient management. As Dr. Lane R. Rosen explains, “Early detection allows us to take early action, possibly reversing the process before the damage becomes permanent.” Learn more about this exciting collaboration in Willis Knighton’s full press release: https://bit.ly/4hVe7C5
Account Manager, CV Ultrasound
1 个月Great to for your Shreveport community!